Cover Image
Market Research Report

Competitor Landscape: Psoriasis

Published by GlobalData Product code 758930
Published Content info 65 Pages
Delivery time: 1-2 business days
Back to Top
Competitor Landscape: Psoriasis
Published: October 31, 2018 Content info: 65 Pages

"Competitor Landscape: Psoriasis", briefings contain evaluations of ongoing development activities within the psoriasis market, together with analysis of current & potential future product positioning.

Key Highlights from the report -

  • Certolizumab pegol may find a niche in PsO patients looking to conceive, due to its global approval for use in women of childbearing age
  • Novartis seeks to identify additional points of differentiation for secukinumab vs. competing biologics by further exploring efficacy and safety in pediatrics and alternative dosing formulations & strategies
  • BMS-986165 could become the first TYK-2 inhibitor to be approved for PsO, pending positive data from the recently registered Phase III trials

The report comprises five key sections.

Executive Summary: Contains analysis of key market events that have occurred during the previous quarter and which have impacted the Psoriasis landscape.

Landscape Updates -

  • 'Order of Entry' analysis, detailing timeline forecasts for each drug in Phase II development or higher.
  • Timeline forecasts for each approved product's lifecycle management initiatives.
  • 'Direction of Travel' positioning analysis for pipeline & currently approved therapies.

Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status.

Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status.

Appendix - Data slides containing the following information -

  • Current Early Stage Psoriasis Pipeline & candidate 'Watch List'.
  • Timeline Assumptions, including standard assumptions & drug specific assumptions.


  • The briefing is based on Sociable Pharma's analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (
  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
  • Forecasts are presented in pipeline forecast figures & detailed tables
  • 'Market Entry' & 'Direction of Travel' positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
  • Reviews ongoing lifecycle management strategies for existing players in the market
  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Table of Contents
Product Code: GDHC068SP

Table of Contents

Introduction to Sociable Pharma's 'Competitor Landscape'

Executive Summary

  • Key Events & Landscape Updates

Landscape Updates

  • Order of Entry
  • Key Competitor Market Entry Strategies
  • Lifecycle Development
  • Direction of Travel for Marketed Products

Pipeline Landscape

  • Pipeline Summary

Approved Product Development Landscape

  • Lifecycle Development


Back to Top